Trade Regulus Therapeutics Inc. - RGLS CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.002124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.6 |
| Open | 1.6 |
| 1-Year Change | 18.52% |
| Day's Range | 1.6 - 1.6 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 17, 2024 | 1.60 | 0.02 | 1.27% | 1.58 | 1.62 | 1.51 |
| Dec 16, 2024 | 1.62 | 0.06 | 3.85% | 1.56 | 1.67 | 1.55 |
| Dec 13, 2024 | 1.56 | -0.01 | -0.64% | 1.57 | 1.61 | 1.50 |
| Dec 12, 2024 | 1.59 | -0.05 | -3.05% | 1.64 | 1.67 | 1.54 |
| Dec 11, 2024 | 1.67 | 0.01 | 0.60% | 1.66 | 1.74 | 1.59 |
| Dec 10, 2024 | 1.61 | 0.05 | 3.21% | 1.56 | 1.67 | 1.54 |
| Dec 9, 2024 | 1.55 | -0.05 | -3.13% | 1.60 | 1.61 | 1.54 |
| Dec 6, 2024 | 1.57 | 0.05 | 3.29% | 1.52 | 1.58 | 1.51 |
| Dec 5, 2024 | 1.49 | -0.07 | -4.49% | 1.56 | 1.58 | 1.48 |
| Dec 4, 2024 | 1.58 | -0.04 | -2.47% | 1.62 | 1.63 | 1.55 |
| Dec 3, 2024 | 1.60 | -0.02 | -1.23% | 1.62 | 1.62 | 1.58 |
| Dec 2, 2024 | 1.61 | 0.03 | 1.90% | 1.58 | 1.63 | 1.57 |
| Nov 29, 2024 | 1.58 | 0.01 | 0.64% | 1.57 | 1.60 | 1.52 |
| Nov 27, 2024 | 1.62 | 0.16 | 10.96% | 1.46 | 1.63 | 1.46 |
| Nov 26, 2024 | 1.51 | 0.02 | 1.34% | 1.49 | 1.51 | 1.44 |
| Nov 25, 2024 | 1.50 | 0.04 | 2.74% | 1.46 | 1.52 | 1.44 |
| Nov 22, 2024 | 1.45 | 0.02 | 1.40% | 1.43 | 1.46 | 1.35 |
| Nov 21, 2024 | 1.38 | -0.01 | -0.72% | 1.39 | 1.40 | 1.29 |
| Nov 20, 2024 | 1.39 | -0.01 | -0.71% | 1.40 | 1.41 | 1.36 |
| Nov 19, 2024 | 1.39 | 0.02 | 1.46% | 1.37 | 1.39 | 1.34 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Regulus Therapeutics Inc. Company profile
About Regulus Therapeutics Inc
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases. Its product candidates are RG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a kidney disease. The Company completed Phase I multiple-ascending dose (MAD) clinical trial. RGLS4326, an anti-miR targeting miR-17, is for the treatment of autosomal dominant polycystic kidney disease (ADPKD). It is in Phase I clinical trial. The Company’s pre-clinical pipeline candidates include RGLS5579 and anti-miR-132. RGLS5579 is developing for the treatment of Glioblastoma and anti-miR-132 is developing for the treatment of non-alcoholic steatohepatitis. Its developing two undisclosed products under Cell Therapies program and Hepatitis B virus program.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Regulus Therapeutics Inc revenues decreased from $10M to $0K. Net loss increased 77% to $27.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects research increase of 16% to $16.5M (expense), general increase of 15% to $7.9M (expense), Stock-based Compensation in SGA increase of 9% to $2.1M (expense).
Equity composition
Common stock $.001 Par, 10/12, 200M auth., 34,130,393 issd. Insider Owns 67.04%.
| Industry: | Bio Therapeutic Drugs |
Suite 210
3545 John Hopkins Court
92121
News
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
22:39, 12 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
12:47, 5 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com